Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL ...
How does your role change when you are part of an adaptive design or some other form of an innovative trial design? In a traditional design, you have fixed assumptions on treatment effect, variability ...
The ICH E20 guideline, released as a Step-2 draft in June 2025, establishes globally harmonised principles for the planning, conduct, analysis, and interpretation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results